Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-powered PET scans may predict prostate cancer aggressiveness before surgery

NCT ID NCT07655648

Knowledge-focused Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surgical findings. The goal is to see if this imaging method can better classify cancer risk and predict whether the cancer might come back after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gallium-68 labeled PSMA and RM26
What this could lead to
If successful, this approach could help doctors determine prostate cancer aggressiveness without invasive biopsy, guiding treatment decisions more accurately.
What could go wrong
This is a small, retrospective study at a single center. The model may not work as well in other hospitals or diverse patient groups, and it is not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jan 2020

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive treatment-naïve prostate cancer patients from a single center with available pre-RP dual-tracer PET/CT, biopsy, and RP pathology data.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Treatment-naïve prostate cancer with subsequent radical prostatectomy (RP) * Availability of presurgical dual-tracer PET/CT images, biopsy, and RP pathology data Exclusion Criteria: * Unavailability of imaging or pathological data * PET/CT performed after any prostate cancer-related treatment * Interval between PET and biopsy \> 3 months * Interval between biopsy and RP \> 1 month

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biochemical recurrence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biochemical recurrence Gleason score Pet / CT Prostate cancer Radiomics

Contacts and locations

Locations

  • Department of Nuclear Medicine, Xiangya Hospital, Central South University

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.